Cite

HARVARD Citation

    Harding, J. et al. (n.d.). O-005Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. Annals of oncology. p. . [Online]. 
  
Back to record